Compare Lucid Group Inc (LCID) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lucid Group Inc vs Natera Inc. Common Stock — how do they compare? Lucid Group Inc trades at $3.28 (market cap $1.32B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 43.2× Lucid Group Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Lucid Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lucid Group Inc for 45 Days and Natera Inc. Common Stock for 0 Days on average.
| LCID | NTRA | |
|---|---|---|
Market Cap | $1.32B | $57.03B |
Volume | 8,737,624 | 1,131,157 |
Sector | Consumer Cyclical | Health |
52-Week High | $21.67 | $425.64 |
52-Week Low | $3.29 | $179.42 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | $4.22B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lucid Group (LCID) trades at $3.29, down 4.22% on the day, reflecting persistent investor concerns over its financial health. The stock shows a bearish technical signal with all moving averages indicating sell signals, while oscillators like the RSI suggest potential oversold conditions. Fundamentally, the company reported a net loss of $2.70 billion on $1.35 billion revenue in 2025, with negative margins and cash burn. Recent news highlights strategic partnerships for autonomous vehicles but also delays in key product launches and cost-saving initiatives critical for turnaround.
The outlook remains highly speculative with significant execution risks. While analyst consensus price target of $7.00 implies upside, the majority hold ratings and ongoing losses pose substantial downside. Investment opportunity hinges on successful cost reduction and new model execution, but bankruptcy risks and cash burn necessitate caution for equity holders.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
